Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl Sells 3,341 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,341 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now owns 58,057 shares of the company’s stock, valued at approximately $2,687,458.53. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 20th, Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24.

Tarsus Pharmaceuticals Trading Up 0.7 %

Tarsus Pharmaceuticals stock opened at $49.91 on Friday. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.10 and a beta of 1.05. The firm has a 50-day moving average price of $48.54 and a two-hundred day moving average price of $45.06. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TARS. Toronto Dominion Bank acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $105,714,000. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after buying an additional 698,712 shares during the last quarter. Lord Abbett & CO. LLC lifted its stake in shares of Tarsus Pharmaceuticals by 115.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock worth $70,873,000 after buying an additional 685,111 shares during the last quarter. Millennium Management LLC lifted its position in shares of Tarsus Pharmaceuticals by 189.4% during the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock valued at $35,659,000 after acquiring an additional 421,495 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TARS. Guggenheim reaffirmed a “buy” rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Barclays cut their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Finally, HC Wainwright restated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.